Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine Cmn (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
J.P. Morgan Vice Chairman Stephen Berenson Joins Flagship Pioneering

Flagship Pioneering, a fully-integrated life science innovation enterprise, today announced that Stephen Berenson has joined the firm as executive partner. The former vice chairman of investment banking...

SYRS : 17.43 (+3.38%)
AGIO : 59.18 (+3.07%)
MCRB : 11.68 (+1.04%)
JPM : 86.86 (-0.18%)
EDIT : 17.95 (+2.34%)
Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Editas Medicine

NEW YORK, NY / ACCESSWIRE / May 31, 2017 / Editas Medicine's shares plunged yesterday after a published paper in the scientific journal Nature Methods revealed that the genome editing tool CRISPR/Cas9,...

EDIT : 17.95 (+2.34%)
VRX : 15.80 (+1.94%)
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

AZN : 35.07 (-0.82%)
EDIT : 17.95 (+2.34%)
PFE : 34.17 (+0.32%)
MKGAF : 120.8100 (+0.12%)
Why Editas Medicine (EDIT) Might Surprise This Earnings Season

Investors are always looking for stocks that are poised to beat at earnings season and Editas Medicine, Inc. (EDIT) may be one such company.

EDIT : 17.95 (+2.34%)
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC) program confirming the potential for CRISPR-based editing...

EDIT : 17.95 (+2.34%)
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?

Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.

AUPH : 6.63 (+3.76%)
CDTX : 6.70 (-2.90%)
EDIT : 17.95 (+2.34%)
PRGO : 75.28 (+0.84%)
4 Drug Stocks Poised to Beat this Earnings Season

M&A and licensing deals as well as drug pricing issues are expected to remain in focus in 2017.

ENDP : 11.84 (+1.63%)
JNJ : 136.43 (+0.28%)
IMDZ : 9.65 (+14.20%)
LLY : 83.89 (-0.50%)
IONS : 54.97 (+0.46%)
EDIT : 17.95 (+2.34%)
GILD : 70.52 (+0.06%)
BIIB : 280.32 (-0.09%)
Editas Medicine to Present at Investor Conferences in May

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:

EDIT : 17.95 (+2.34%)
Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, May 15, 2017, at 5:00 p.m. ET to discuss a corporate update...

EDIT : 17.95 (+2.34%)
What's in Store for Immune Design (IMDZ) Stock in Q1 Earnings?

Immune Design Corp (IMDZ) is expected to report first-quarter 2017 results on May 9.

IMDZ : 9.65 (+14.20%)
IONS : 54.97 (+0.46%)
EDIT : 17.95 (+2.34%)
RHHBY : 32.7600 (+1.42%)
What's in Store for BioDelivery (BDSI) this Earnings Season?

BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.

ENDP : 11.84 (+1.63%)
BDSI : 2.95 (+3.51%)
CDTX : 6.70 (-2.90%)
EDIT : 17.95 (+2.34%)
Teva Pharmaceutical (TEVA) Q1 Earnings: What's in the Cards?

Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report first-quarter 2017 earnings on May 11

MYL : 39.03 (+0.05%)
IONS : 54.97 (+0.46%)
EDIT : 17.95 (+2.34%)
TEVA : 32.61 (+0.28%)
Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?

Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.

HZNP : 11.73 (-1.18%)
IMDZ : 9.65 (+14.20%)
EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)
What's in the Cards for Allergan (AGN) this Earnings Season?

Allergan plc (AGN) will be reporting first-quarter 2017 earnings result on May 9, before the market opens.

AGN : 246.46 (-0.26%)
IMGN : 6.06 (+4.12%)
EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)
Arena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?

Arena Pharmaceuticals, Inc. (ARNA) is expected to report first-quarter 2017 on May 9, after market closes.

ARNA : 14.88 (-8.09%)
EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)
TEVA : 32.61 (+0.28%)
Can Ligand (LGND) Spring a Surprise this Earnings Season?

Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

LGND : 123.87 (+0.60%)
NVS : 86.34 (unch)
EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)
What to Expect from Epizyme (EPZM) This Earnings Season?

Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell.

EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)
RHHBY : 32.7600 (+1.42%)
EPZM : 14.70 (+7.69%)
What's in Store for Adverum (ADVM) in Q1 Earnings?

Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.

ADVM : 2.75 (-3.51%)
EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)
REGN : 517.33 (-1.75%)
What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.

RARE : 66.42 (+1.16%)
EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)
CPRX : 2.84 (+3.27%)
GW Pharmaceuticals (GWPH) Q2 Earnings: What to Expect?

GW Pharmaceuticals plc (GWPH) is expected to report second-quarter fiscal 2017 results on May 4.

PTI : 4.29 (-0.23%)
GWPH : 103.81 (+0.87%)
EDIT : 17.95 (+2.34%)
FGEN : 32.25 (-0.31%)

Van Meerten Stock Picks

5 Great Growth Stocks
Each week Value Line publishes a list of growth stocks the for the past 10 years have had a 10% increase in Sales, Cash Flow, Earnings, Dividends and Book Value and are expected to continue that 10% growth for the next 5 years.
NVDA -4.54 , CGNX +1.13 , EDU +0.07 , LUV +0.40 , ZBRA +0.17
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Sep E-mini S&Ps ( ESU17 +0.26%) this morning are up +0.22% and European stocks are up +0.98% on signs of increased M&A activity along with a rally in European bank stocks. Nestle SA is up nearly 5% after Third... Read More

Chart of the Day

LendingTree (TREE) is the Barchart Chart of the Day. The mortgage lender has a Trend Spotter buy signal, A weighted Alpha of 147.70+ and gained 129.77% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures ended the week with losses of 3 1/4 to 5 1/2 cents, with July down 6.84% since last Friday. Friday’s Commitment of traders report showed spec funds adding back 35,896 contracts to their net short position as of Tuesday, after last ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.